Waters(WAT) - 2025 Q4 - Earnings Call Transcript

Financial Data and Key Metrics Changes - The company achieved high single-digit reported revenue growth and low double-digit adjusted EPS growth in the fourth quarter, with sales growing 7% on a reported basis and 6% in constant currency [6][9] - Adjusted EPS grew 10% to $4.53, while GAAP EPS was $3.77 [33][34] - For the full year, sales grew 7% on both a reported and constant currency basis, with adjusted EPS growing 11% to $13.13 [10][34] Business Line Data and Key Metrics Changes - Recurring revenue grew 9%, driven by chemistry growth, while instrument revenue grew 5%, led by high single-digit LCMS growth [9][10] - Chemistry revenue grew 12% for the full year, significantly above the historical average growth rate of 7% [12][34] - The transition to a subscription-based model for Empower reduced overall instrument growth by a low single-digit percentage for the quarter, but is expected to provide long-term recurring revenue benefits [9][10] Market Data and Key Metrics Changes - Pharma revenue grew 9%, with high single-digit growth across the Americas and Europe, and low double-digit growth in Asia [15][31] - Industrial revenue grew 6%, while academic and government declined 1% [33] - In China, the company grew 9% for the year, driven by strong performance in biotech and CDMOs [16][34] Company Strategy and Development Direction - The company completed the acquisition of BD's Biosciences and Diagnostic Solutions business, aiming to strengthen its position in high-growth adjacencies and enhance operational execution [6][19] - The strategic roadmap laid out five years ago continues to advance, with a focus on innovation and commercial execution [8][10] - The company plans to expand its idiosyncratic growth driver framework from three to five drivers, adding biologics and informatics to the existing drivers [16][17] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the ability to deliver strong growth in 2026, with a blended year-over-year revenue growth of approximately 5.3% at the midpoint of the combined company [29][38] - The company expects to realize approximately $50 million in revenue synergies in 2026, reflecting initial contributions from commercial excellence initiatives [38][39] - Management highlighted the importance of improving operational execution and pricing discipline to enhance revenue and profitability [48][58] Other Important Information - The company expects to achieve approximately $55 million of adjusted EBIT from cost synergies in 2026 [25][39] - Free cash flow totaled $677 million for the full year, with a net debt position of $820 million at the end of the year [36][39] Q&A Session Summary Question: Insights on BD results and path to recovery - Management acknowledged several issues that emerged in Q4 impacting growth, but emphasized that these will now be present in a lower baseline for 2026, allowing for potential upside [45][47] Question: Impact of Empower transition on instruments - Management noted that the transition to subscription has created a low single-digit headwind to overall instrument numbers, but expressed confidence in the strong performance of LCMS and the overall instrument funnel [46][52] Question: Full year guidance and deceleration - Management explained that the guidance reflects prudence and incorporates assumptions about various market segments, including academic and government, and the impact of the Empower transition [55][56] Question: Update on pro forma leverage and interest expense - Management indicated that net debt is expected to be around 2.4x net debt to EBITDA, with plans to reduce it below 2 times within 18 months [63][64] Question: Synergy targets and operational execution - Management confirmed that they are on track to deliver the commitments made during the deal announcement, with a focus on identifying opportunities for cost synergies [67][70]